NCT01593761View on ClinicalTrials.gov

Phase 2a Study of CG400549 for the Treatment of cABSSSI Caused by Methicillin-resistant Staphylococcus Aureus

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

September 30, 2012

Study Completion Date

October 31, 2012

Conditions
Skin Infection
Interventions
DRUG

CG400549

960mg QD at fed state approx 1 hour after meal

Trial Locations (1)

91942

eStudysite, La Mesa

Sponsors
All Listed Sponsors
lead

CrystalGenomics, Inc.

INDUSTRY